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Background: Adenocarcinoma is the most common type of non-small cell lung cancer and is frequently observed in
non-smoking patients. Adenocarcinoma in-situ (formerly referred to as bronchioloalveolar carcinoma) is a subset of lung
adenocarcinoma characterized by growth along alveolar septae without evidence of stromal, vascular, or pleural invasion,
that disproportionately affects never-smokers, women, and Asians. Adenocarcinoma in-situ is morphologically and
histologically similar to a contagious lung neoplasm of sheep called ovine pulmonary adenocarcinoma (OPA). OPA is
caused by infection with the exogenous betaretrovirus, jaagsiekte sheep retrovirus (JSRV), whose envelope protein (Env) is
a potent oncogene. Several studies have reported that a proportion of human lung adenocarcinomas are
immunopositive for an antigen related to the Gag protein of JSRV, however other groups have been unable to
verify these observations by PCR.
Methods: Here we examine human lung cancer tissue arrays (TA) for evidence of JSRV Env protein and DNA by
immunohistochemical staining and PCR, respectively.
Results: Our results reveal that a subset of human lung cancers express an antigen that reacts with a JSRV Env-specific
monoclonal antibody in immunohistochemistry and that exogenous JSRV-like env and gag sequences can be amplified
from TA tumor samples, albeit inefficiently.
Conclusions: While a causative role has not been established, these data suggest that a JSRV-like virus might infect
humans. With next generation sequencing approaches, a JSRV-like virus in human lung cancers may be identified
which could have profound implications for prevention, diagnosis and therapy.
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Lung cancer remains the leading cause of cancer related
deaths worldwide with a 5-year survival rate for all stages
combined of only 16% [1]. Lung cancer can be broadly di-
vided into two groups; non-small cell lung cancer (NSCLC)
and small cell lung cancer (SCLC). Pulmonary adenocar-
cinoma is the most prevalent NSCLC in both men and
women [2]. Bronchioloalveolar carcinoma (BAC) is a sub-
type of pulmonary adenocarcinoma that often presents as
multifocal lesions in the peripheral regions of the lung with
a “ground glass” appearance by radiologic imaging. It is de-
fined histologically by a pure lepidic growth pattern with
neoplastic cells growing on preserved alveolar walls with* Correspondence: kwootton@uoguelph.ca
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distribution, and reproduction in any mediumno evidence of stromal, vascular or pleural invasion [3,4].
A recent consensus classification system for adenocarcin-
oma, in fact, has proposed replacement of the term BAC
with “adenocarcinoma in-situ” [5]. These non-invasive lung
lesions are more commonly found in non-smokers, women
and the Asian population [6].
The main risk factors for lung cancer include cigarette
smoke, asbestos, environmental pollution and radiation
[7-10]. However, approximately 15% of all lung cancer cases
are not attributable to any of these risk factors. It has been
estimated that 15–25% of human cancer may have a viral
etiology and two viruses in particular, the human papilloma
virus (HPV) and jaagsiekte sheep retrovirus (JSRV), have
been speculated to play a role in the pathogenesis of human
lung cancer [11].Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
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carcinoma (OPA) [12], a disease characterized by the in-
duction of a low grade multifocal mixed adenocarcinoma
with papillary and/or acinar characteristics within the dis-
tal lungs of infected sheep. OPA shares clinical and histo-
logic features with human adenocarcinoma in-situ and
is regarded as a valuable large animal model for this hu-
man disease [13-15]. The cellular receptor for JSRV is the
glycosyl-phosphatidylinositol (GPI)-linked protein, hyal-
uronidase 2 (Hyal2) [16]. Hyal2 homologues from a variety
of different species, including humans, have been shown
to mediate entry of JSRV Env pseudotyped retroviral parti-
cles [17]. JSRV induces lung tumors in sheep through ex-
pression of the envelope (Env) protein [18]. Several studies
have shown that the JSRV Env protein has the ability to
transform a variety of cell types in vitro [19-21], including
human cells [22], and can induce lung tumors in mice
[23,24]. However, the exact mechanism by which Env me-
diates tumorigenesis is still unknown.
The ability of JSRV to cause peripheral lung tumors in
sheep with clinical and histological similarities to those
frequently found in human lung adenocarcinoma [13-15],
the capacity for JSRV to use the human homolog of Hyal2
to enter human cells [16,25], and the fact that JSRV Env
can transform human lung epithelial cells in vitro [22] has
led to speculation that JSRV could be linked to a subset of
human lung cancers [11]. Indeed, studies have detected
JSRV capsid protein as well as orf-x, gag and endogenous
JSRV sequences in human tissues [26-28]; however, there
is no clear consensus on the association of JSRV with hu-
man lung cancer as other studies report no correlation be-
tween JSRV and human lung cancer [29-31]. Interestingly,
a number of epidemiological studies have found that
workers in abattoirs and meat processing plants have an
increased risk of developing lung cancer that is postulated
to be due to exposure to oncogenic viruses of food ani-
mals such as JSRV and bovine papilloma virus [32-34].
Given that JSRV Env is capable of inducing tumors in
both sheep and mice, and due to the controversy surround-
ing the role of JSRV in human lung cancer, we decided to
examine multiple types of human lung tumor samples for
the presence of JSRV Env by immunohistochemical staining
of lung cancer tissue arrays with an Env-specific monoclonal
antibody and by PCR amplification with env- and gag-spe-
cific primers. Here we demonstrate that a subset of human
lung cancers express an antigen that reacts with a JSRV Env
monoclonal antibody and that env and gag sequences can
reproducibly be amplified from genomic DNA extracted
from human lung cancer tissue arrays, albeit inefficiently.
Methods
Tissue samples
Human lung cancer tissue arrays (LC2085a) containing
lung tumors from 188 patients and 20 samples of normaltissue were purchased from US Biomax (Rockville, MD).
Of the 208 core tissues, there were 72 adenocarcinomas,
72 squamous cell carcinomas, 22 small cell carcinomas, 2
large cell carcinomas, 10 normal lung tissues and 10 nor-
mal adjacent tissues. A human nasopharyngeal cancer tis-
sue array (NH1001, US Biomax) containing 15 squamous
cell carcinomas, 3 basal cell carcinomas, 2 adenocarcin-
omas, 15 papillomas, 6 polyps, 3 each of hyperplasia and
inflammation and 1 adjacent normal tissue was used as a
control. Note that all specimens on the lung and nasopha-
ryngeal cancer tissue arrays were of Chinese origin. In
addition, 10 examples of adenocarcinoma in-situ and 10
non-neoplastic lung tissue specimens (unstained slides
and tissue cores) were obtained from formalin fixed paraf-
fin embedded tissue blocks at the Roswell Park Cancer In-
stitute (Buffalo, NY). Approval for the use of human tissue
samples was obtained from the Roswell Park Cancer Insti-
tute. Tissue arrays were subjected to immunohistochemi-
cal analysis as described below.
Cell lines
Human A549 cells (ATCC CRL-1573) and the ovine pul-
monary adenocarcinoma cell line, JS7, (kindly provided by
Dr. Mark Ackerman, Iowa State University, USA) were
propagated in Dulbecco’s modified Eagle medium supple-
mented with 10% fetal bovine serum, 2 mM L-glutamine
and 1% penicillin/streptomycin. HBE135-E6E7 cells (ATCC
CRL-2741) were grown in keratinocyte-serum free medium
(Invitrogen) with 5 ng/ml human recombinant EGF and
0.05 mg/ml bovine pituitary extract. Cells were maintained
at 37°C in 5% CO2.
Immunohistochemistry
Paraffin embedded tissue was dewaxed and rehydrated
using xylene followed by decreasing concentrations of
ethanol. Citrate buffer was used for antigen retrieval and
tissues were blocked using 5% bovine serum albumin
(BSA). Tissue sections were incubated at 4°C overnight
with either a 1:50 dilution of a highly specific anti-JSRV
Env monoclonal antibody [35], an isotype control antibody
or supernatant from an unrelated antibody-producing hy-
bridoma as described previously [36]. Primary antibodies
were detected using a 1:50 dilution of an anti-mouse sec-
ondary antibody conjugated to biotin (Santa Cruz Tech-
nologies). Sigma Fast 3,3-diaminobenzidine tablets (Sigma,
St. Louis, MO) were used to visualize protein localization
in the tissue. Hemotoxylin was used as a counterstain. Tis-
sues were analyzed by three independent observers and
were graded as 0 for no staining, 1 for low intensity stain-
ing, 2 for moderate intensity staining in >10% of tissue or
high intensity staining in <10% of tissue, and 3 for high in-
tensity staining in >10% of tissue.
To confirm the specific reactivity of the anti-JSRV Env
monoclonal antibody on histology sections, a peptide
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in this assay was a fusion protein called JSU-IgG which is
comprised of the JSRV Env surface domain (SU) fused to
the human immunoglobulin G (IgG) constant region [38].
JSU-IgG was used to boost mice during the preparation of
mouse hybridomas producing antibodies specific for the
JSRV Env SU domain [35]. The anti-JSRV Env monoclo-
nal antibody was neutralized by incubating with an ex-
cess of JSU-IgG (1:5 and 1:10 ratios) for 1 hour at room
temperature, followed by the standard immunohisto-
chemistry procedure described above. A JSU-IgG alone
control was also performed.
Genomic DNA extraction
Three serial sections of a human lung cancer tissue array
were purchased and processed individually such that all
of the tissues on one array (excluding normal tissue)
were pooled together giving a total of three pooled tissue
array samples, TA#1, TA#2 and TA#3, one for each
array. Tissue array slides (3 in total) were first dewaxed
in xylene for 30 minutes followed by rehydration of the
tissues for 30 minutes each in 100% ethanol, 95% etha-
nol, and 70% ethanol. The slides were then washed with
PBS for 15 minutes before tissue was scraped from the
slides, pooled together and placed into 200 ul of PBS.
Note that it was necessary to pool all of the tissue sam-
ples on the array in order to obtain sufficient genomic
DNA for PCR analysis. Genomic DNA was extracted
from tissue arrays, tissue cores and cell lines using the
QIAamp DNA mini kit (Qiagen) in accordance with the
manufacturer’s instructions.
PCR detection of env and gag sequences
JSRV env and gag sequences were detected by PCR
amplification using 100-300 ng of genomic DNA and
either env (5′-ATACGGGAACGGATCTGGACC-3′ and
5′-CAACATGAATGGATACGGCACGC-3′) or gag (5′-C
CCCATCTCTGAAAATGCAC-3′ and 5′-TGTTTAGACG
GTGGAGGAAA-3′) specific primers which amplify 382
and 313 base pair (bp) fragments, respectively. Primers
were designed according to the JSRV genomic sequence
with accession number AF105220. DNA template integrity
was assessed in a separate PCR reaction using GAPDH
specific primers (5′-CCACCCATGGCAAATTCCATGG
CA-3′ and 5′-TCTAGACGGCAGGTCAGGTCCACC-3′)
which give rise to a 593 bp PCR product. For PCR amplifi-
cation, the 5PRIME MasterMix was employed and the cyc-
ling conditions were as follows: 94°C for 2 min followed by
30 cycles of 94°C for 30s, 55°C for 30s and 65°C for 2 min.
A final extension of 7 min at 65°C concluded the program.
PCR products were purified with the QIAquick Gel Extrac-
tion Kit (Qiagen). Purified PCR products were cloned into
the pGEM-T Easy vector (Promega) following the manufac-
turer’s instructions and purified plasmid DNA (wherepossible, 3 clones per sample) was sequenced two times in
both directions with an ABI Prism DNA Sequencer.
Several measures were taken to avoid contamination.
All experiments were conducted at the beginning of the
day in a laboratory located in a separate building that
had not previously housed JSRV DNA or ovine tissue.
DNA extractions and PCR amplifications were con-
ducted using previously unopened tissue arrays, primers,
DNA extraction kits, PCR amplification reagents and fil-
tered tips.
PCR detection of ovine genomic DNA
To test whether fragments of sheep DNA were present in
the human DNA samples used in this study, a nested PCR





for sheep mitochondrial cytochrome-coxidase subunit 1 [27].
Results
Detection of JSRV Env protein in human lung cancer
tissue arrays
To evaluate the association between JSRV Env and human
lung cancer, three sections of a human lung cancer tissue
array purchased from US Biomax were analyzed by immu-
nohistochemical staining using an anti-JSRV Env mono-
clonal antibody [35]. Staining, which was observed in a
subset of the samples (Figure 1), was confined to epithelial
cells within the tumor and varied from apical (Figure 1E)
to cytoplasmic (Figure 1F). Serial sections of the lung can-
cer tissue array were further analyzed by immunohisto-
chemistry using an isotype control (Figure 1G and J) as
well as supernatant from an unrelated antibody-producing
hybridoma (Figure 1H and K) to control for non-specific
staining. In both cases, no positive staining was observed.
Staining intensity of the JSRV Env antibody was quanti-
fied by three individuals according to the grading scheme
described earlier and illustrated in Figure 1A, B, C and D.
Immunohistochemical staining with the JSRV Env specific
monoclonal antibody yielded the following results. 21% of
adenocarcinomas and squamous cell carcinomas were
positive according to our criteria (grade 2 or higher), of
which 2% of adenocarcinoma and 4% of squamous cell car-
cinomas were highly positive (grade 3) (Table 1). It should
be noted that with the small number of tumor biopsies that
stained highly positive (8/187 squamous cell carcinomas
and 4/207 adenocarcinomas), it is unlikely that there is any
statistically significant difference between adenocarcinoma
and squamous cell carcinomas. Conversely, only 5% small
cell carcinomas stained positive for JSRV Env. 100% of
both normal tissue and adjacent normal tissue had either
no staining or low intensity staining (Table 1).
Figure 1 (See legend on next page.)
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Figure 1 Representative images of immunohistochemical staining of tissues with a monoclonal antibody against the JSRV Env protein.
Human lung tumor tissue array samples representing grade 0 staining (A), grade 1 staining (B), grade 2 staining (C), and grade 3 staining (D).
High magnification (40x) images of human lung tumors with grade 2 (E) and grade 3 (F) staining. Low (4X) and high (40X) magnification images
of human lung tumor tissue array sample stained with an isotype control (G and J) and an unrelated antibody-producing hybridoma (H and K).
Lack of immunohistochemical staining of human lung tumor tissue arrays in the presence of JSRV Env antibody plus purified JSU-IgG protein
(I and L) or JSU-IgG protein alone (M). Human adenocarcinoma in-situ displaying clusters of JSRV Env positive cells (N). Representative images of
human adenocarcinoma in-situ (O) and non-neoplastic human lung tissue (P) with no detectable Env staining. Nasopharyngeal carcinoma tissue
array showing no detectable Env staining (Q). Lung tissue from an OPA affected sheep stained with the JSRV Env monoclonal antibody (R).
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the adenocarcinoma and squamous cell carcinoma tissues
with respect to stage of disease. For stage I, II and III
adenocarcinoma, 17%, 21%, and 25% of tissue samples, re-
spectively, were graded as 2 or higher (Table 2). Conversely,
for stage I, II and III squamous cell carcinoma, 26%, 19%,
and 20% of tissue samples, respectively, were graded as 2 or
higher (Table 3). These results suggest that a subset (ap-
proximately 21%) of human lung adenocarcinoma and
squamous cell carcinoma tissues express an antigen that
cross-reacts with the JSRV Env-specific monoclonal anti-
body and that in the case of adenocarcinoma, increased
staining intensity correlates with more advanced stage can-
cer, whereas decreased staining intensity correlates with
more advanced stage cancer in the case of squamous
cell carcinoma. Moreover, there was no apparent rela-
tionship between positive staining with the JSRV Env
monoclonal antibody and adenocarcinomas as the small
percentage of squamous cell carcinomas that stained
strongly positive (4%) was twice that of strongly positive
adenocarcinomas (2%).
Given the histological and clinical similarities between
OPA and the adenocarcinoma in-situ form of human
lung adenocarcinoma, we decided to further evaluate
JSRV Env staining in ten adenocarcinoma in-situ sam-
ples and 10 non-neoplastic lung tissue samples obtained
from the Roswell Park Cancer Institute in Buffalo, NY. Im-
munohistochemical analyses revealed positive staining in
2 out of 10 adenocarcinoma in-situ samples (Figure 1N),
while all of the remaining adenocarcinoma in-situ samples
(Figure 1O) and non-neoplastic tissues (Figure 1P) were
negative.Table 1 Total JSRV envelope staining of human lung tumor ti
Lung tissue 0
Adenocarcinoma 43/207 (21%) 1
Squamous cell carcinoma 39/187 (21%) 1
Small cell carcinoma 45/64 (70%)
Adjacent normal tissue 39/46 (58%)
Normal lung tissue 43/52 (83%)
*Tissues were graded as 0 for no staining, 1 for low intensity staining, 2 for modera
tissue, and 3 for high intensity staining in >10% of tissue.Since there have been no reports of ovine betaretro-
viral antigen or proviral DNA detection in nasopharyn-
geal carcinomas from human patients, we decided to use
two nasopharyngeal carcinoma tissue arrays, produced
by the same company that made the lung cancer tissue
arrays, as additional controls. Unlike the human lung
cancer tissue arrays, there was no detectable staining in
the nasopharyngeal carcinoma tissue arrays (Figure 1Q)
further suggesting that the positive staining on the lung
cancer tissue arrays was indeed specific.
Amplification of JSRV env and gag sequences from
genomic DNA isolated from human lung cancer
tissue arrays
To verify the immunohistochemistry results, genomic
DNA was isolated from three independent serial sections
of a human lung cancer tissue array and one nasopharyn-
geal carcinoma tissue array produced by US Biomax as
well as from ten adenocarcinoma in-situ and ten non-
neoplastic tissue cores. In addition, genomic DNA was ex-
tracted from two human lung tumor cell lines (A549,
H358) and one immortalized human bronchial epithelial
cell line (HBE135-E6E7). Genomic DNA from the OPA
derived lung tumor cell line, JS7 was used as a positive
control and genomic DNA isolated from ten normal sheep
lungs was used as a negative control. See Table 4 for a
summary of all samples analyzed. Note that aside from the
OPA sample, all genomic DNA extractions and PCR reac-
tions were conducted in a separate building detached from
our laboratory to avoid the potential for contamination.
Using primers specific for exogenous JSRV env, products
of the expected size (382 bp) were amplified specificallyssue arrays
Staining intensity*
1 2 3
20/207 (58%) 40/207 (19%) 4/207 (2%)
08/187 (58%) 32/187 (17%) 8/187 (4%)
16.64 (25%) 3/64 (5%) 0/64 (0%)
7/46 (15%) 0/46 (0%) 0/64 (0%)
9/52 (17%) 0/52 (0%) 0/52 (0%)
te intensity staining in >10% of tissue or high intensity staining in <10% of
Table 2 Total JSRV envelope staining in adenocarcinomas
based on stage
Staining intensity*
Stage 0 1 2 3
I 14/54 (26%) 31/54 (57%) 8/54 (15%) 1/54 (2%)
II 21/93 (23%) 52/93 (56%) 18/93 (19%) 2/93 (2%)
III 8/60 (13%) 37/60 (62%) 14/60 (23%) 1/60 (2%)
*Tissues were graded as 0 for no staining, 1 for low intensity staining, 2 for
moderate intensity staining in >10% of tissue or high intensity staining in
<10% of tissue, and 3 for high intensity staining in >10% of tissue.






















Normal sheep lung 10 0/10 0/10
aPCR products of the correct size were amplified but did not contain
gag sequence.
bPCR product amplified in only 1 out of 3 attempts.
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beit at very low levels (representative gel; Figure 2A upper
panel, lane 2). A second round of PCR resulted in a much
stronger signal (Figure 2A upper panel, lane 3). No PCR
products were amplified from the human cell lines, the
nasopharyngeal carcinoma tissue array, the non-neoplastic
tissue, or normal sheep lung even after a second round of
PCR (Figure 2A upper panel, lanes 4, 5,6, 8 and 10). First
round PCR products amplified from the genomic DNA of
three separate lung cancer tissue arrays were cloned. Se-
quence analysis of three independent clones revealed that
these PCR products were 99-100% identical to that of the
exogenous JSRV env sequence deciphered by DeMartini et
al [39]; accession number AF357971 (Figure 2B). The
JSRV env-like sequence amplified from two out of the
three tissue arrays differed by a single nucleotide located
within the surface domain (Figure 2B) and in one instance,
this polymorphism resulted in an amino acid change from
asparagine to aspartic acid (Figure 2C). Amplification of
JSRV env sequence from the two Roswell Park Cancer In-
stitute adenocarcinoma in-situ tissues that were positive
by immunohistochemistry (#2 and #9) was not reprodu-
cible in that only 1 out of 3 PCR reactions resulted in a
product of the expected size and despite multiple at-
tempts, these products could not be cloned (data not
shown).
To confirm that the anti-JSRV Env antibody was spe-
cific and without cross-reactivity, additional tissue arrays
were tested by peptide neutralization using purified JSU-
IgG [38]. Immunohistochemistry was done as before,
with the exception that slides were incubated with JSRV
Env antibody + purified JSU-IgG protein or JSU-IgGTable 3 Total JSRV envelope staining in squamous cell
carcinomas based on stage
Staining intensity*
Stage 0 1 2 3
I 9/38 (24%) 19/38 (50%) 7/38 (18%) 3/38 (8%)
II 16/94 (17%) 60/94 (64%) 14/94 (15%) 4/94 (4%)
III 14/54 (26%) 29/54 (54%) 10/54 (18%) 1/54 (2%)
*Tissues were graded as 0 for no staining, 1 for low intensity staining, 2 for
moderate intensity staining in >10% of tissue or high intensity staining in
<10% of tissue, and 3 for high intensity staining in >10% of tissue.protein. The positive staining seen in Figure 1D was
blocked by the added JSU-IgG (Figure 1I and L) and no
staining was seen with the JSU-IgG alone (Figure 1M).
Next we attempted to amplify part of the gag sequence
from a relatively conserved region of the JSRV genome. Al-
though DNA from all three tissue arrays and both adeno-
carcinoma in-situ samples produced a PCR product of the
appropriate size using gag-specific primers, only the prod-
uct from one of the three tissue arrays and one of the two
adenocarcinoma in-situ samples was successfully cloned.
Interestingly, while we were not able to clone env DNA
from the adenocarcinoma in-situ samples, we were able to
clone gag DNA. Sequence alignment with JSRV gag from
sheep tumors identified a single nucleotide difference in
the matrix region just upstream of variable region 2 [42] in
both the tissue array and adenocarcinoma in-situ DNA
(Figure 2D). In the case of the tissue array sequence, this
nucleotide difference would result in a single amino acid
substitution of an asparagine for a serine (Figure 2E). Al-
though we observed bands of the expected size in the hu-
man lung tumor cell lines (Figure 2A middle panel, lanes
4-6), sequence analysis failed to reveal the presence of
JSRV-like gag sequence.
Sheep mitochondria DNA was not detected in human
genomic DNA samples
To rule out the possibility that the human genomic DNA
samples that were positive for JSRV env and gag sequences
were contaminated with sheep DNA, we screened human
DNA samples for the presence of sheep DNA using
primers specific for the sheep mitochondrial cytochrome-
oxidase subunit as described previously [27]. To determine
the sensitivity of the assay, serial dilutions of normal sheep
lung DNA were subjected to first round PCR followed by
nested PCR. The first round of PCR was able to detect












































































































































Figure 2 PCR amplification of JSRV env and gag sequences from genomic DNA. (A) Representative image of PCR products amplified using
env- (upper panel), gag- (middle panel) and GAPDH-specific (lower panel) primers. Lanes 1; water only, 2; lung cancer tissue array - first round
PCR, 3; lung cancer tissue array - second round PCR, 4; HBE135-E6E7, 5; A549, 6; nasopharyngeal cancer tissue array, 7; molecular weight marker, 8;
non-neoplastic human lung, 9; OPA lung tumor cell line, JS7, and 10; normal sheep lung. Nucleotide (B) and amino acid (C) sequence alignment
of PCR products amplified with env-specific primers. Nucleotide (D) and amino acid (E) sequence alignment of PCR products amplified with
gag-specific primers. AF105220; accession number of the full-length JSRV genome deciphered by Palmarini et al. [12], AF357971; accession number of
the full-length JSRV genome deciphered by De Martini et al. [39], AF153615; accession number of an endogenous JSRV genome deciphered by
Palmarini et al. [40], EF680297 accession number of an endogenous JSRV deciphered by Arnaud et al. [41], DQ838494; accession number of a
full-length JSRV genome of Chinese origin, TA; tissue array, Biopsy 9; adenocarcinoma in-situ #9.
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to less than 1 pg of genomic DNA (Figure 3B). Although
sheep mitochondrial DNA sequences were detected after
the first round of PCR using 100 ng of genomic DNA iso-
lated from the JS7 sheep lung tumor cell line (Figure 3C,
lane 8), we were unable to detect any traces of sheep DNA
in human DNA that tested positive for JSRV env or gag
(Figure 3D, lanes 2-6), even after nested PCR.
Discussion
Here we demonstrate that a subset of human lung adeno-
carcinomas, squamous cell carcinomas and bronchioloal-
veolar carcinomas express an antigen that reacts with a
JSRV Env specific monoclonal antibody in immunohisto-
chemistry. Further, we demonstrate amplification of JSRV
env and gag sequences from genomic DNA isolated from
an array of pooled human lung cancer tissue samples as
well as gag sequences from individual adenocarcinoma in-
situ samples. As with other studies, we did not find a strict
correlation between adenocarcinoma in-situ and the pres-
ence of JSRV-like antigen. However, we did identify aFigure 3 Absence of sheep mitochondria in human DNA
samples. PCR (A) and nested PCR (B) of serial dilutions of sheep
genomic DNA. First round PCR (C) and nested PCR (D) of genomic DNA
isolated from non-neoplastic tissue (lane 1), lung cancer tissue array #1
(lane 2), lung cancer tissue array #2 (lane 3), lung cancer tissue array #3
(lane 4), adenocarcinoma in-situ sample #2 (lane 5), adenocarcinoma
in-situ sample #9 (lane 6), water (lane 7) and the OPA lung tumor cell
line, JS7 (lane 8). M; marker.subset of adenocarcinoma and squamous cell carcinomas
that were immunopositive suggesting that this association
is broader than previously thought.
While immunohistochemical studies using JSRV Gag
specific antibodies consistently identify 20-30% of human
lung tumor samples as immunopositive [26,27,30], the no-
tion that a JSRV-like virus is associated with a subset of
human pulmonary tumors remains controversial. In one
study involving 249 human lung tumor samples, 30% of
adenocarcinoma in-situs, 26% of lung adenocarcinomas
and two of seven large cell carcinomas were immunoposi-
tive for JSRV capsid protein [26], but subsequent attempts
to detect genomic DNA or RNA using PCR and RT-PCR
failed to detect JSRV gag sequences in human lung tumor
samples [30]. Interestingly, a study of normal blood do-
nors from Cameroon (N = 44) and AIDS patients from
Nigeria (N = 20) detected orf-x and gag-like sequences in
10% and 26% of whole blood specimens, respectively, but
failed to detect JSRV-like sequences in a European cohort
of 20 hemophiliacs, 15 blood donors, and 4 patients with
adenocarcinoma in-situ or SCLC [27]. In our study, we
employed a different approach and stained an array of hu-
man lung cancers with a highly specific monoclonal anti-
body against the oncogenic Env protein of JSRV, rather
than Gag. The JSRV Env monoclonal antibody used in
this study was produced against antigen that had been
highly purified using affinity chromatography and high-
performance liquid chromatography [35]. We cannot
explain why our monoclonal antibody was able to detect
JSRV Env-like antigens in human lung cancer speci-
mens whereas a previous report using polyclonal anti-
sera against JSRV Env was unsuccessful [29]; however,
one possibility is that our monoclonal antibody is better
at detecting denatured antigen. Interestingly, in that
same study, 13/43 human lung adenocarcinomas that did
not stain with antisera against JSRV Env, stained positive
with both JSRV-CA and JSRV-MA antisera [29]. The fact
that the JSRV Env monoclonal antibody did not cross-
react with non-neoplastic lung tissue or nasopharyngeal
carcinoma biopsies and only reacted strongly with a small
subset of lung tumor samples suggests that the antibody is
specific for an antigen present in human lung tumors.
While we cannot rule out the possibility that the JSRV
Env monoclonal antibody cross-reacts with an endogen-
ous retroviral protein whose expression is upregulated in a
subset of human lung tumors, our PCR data support the
idea that the antigen detected by the JSRV Env monoclo-
nal antibody is not simply a cross-reacting human protein.
It is important to note that the staining intensity and
pattern in the TA differed somewhat from that of OPA
(compare Figure 1F with Figure 1O). If a JSRV-like virus
were to infect humans and initiate proliferation of lung
epithelial cells, it is possible that the proliferating cells
would be subject to immunoediting [43], which could
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the monoclonal antibody to recognize the JSRV Env-like
protein. Interestingly, tumors that arise in transgenic mice
expressing JSRV Env from an SPC promoter do not dis-
play uniform Env staining within the tumor and in some
cases resemble the staining pattern seen in the TAs with
grade 3 staining [24]. It is possible that if we had amplified
the entire Env sequence we would have identified add-
itional amino acid differences that might have resulted in
modified glycosylation patterns and/or changes in epitope
binding sites which could lead to decreased binding affin-
ity of the monoclonal antibody.
In another study evaluating the presence of JSRV-like se-
quences in human lung tumors by PCR, geographical loca-
tion was noted as an important factor. JSRV-like DNA was
shown to be highly prevalent in Sardinian cases where
sheep farming has been conducted for centuries and almost
entirely absent in non-Sardinian cases from Campania,
where sheep farming is largely non-existent [28]. Therefore,
detection of JSRV-like DNA sequences in human lung tu-
mors may be more likely in active sheep farming communi-
ties where there is an increased chance of human and
sheep interaction. The same study also suggested that there
could be a genetic component to determining the presence
of JSRV in human populations as the isolated island popu-
lation of Sardinia had higher rates of JSRV-like sequences
among biopsies [28]. Interestingly, all of the human lung
tumor biopsies and normal tissue included on the tissue ar-
rays used in our study originated from China, the country
with the largest sheep population worldwide (Food and
Agriculture Organization of the United Nations) and where
JSRV is endemic [44]. We also tested 10 adenocarcinoma
in-situ and 10 normal human lung tissue samples from the
USA, where OPA is uncommon. Two of the samples
stained weakly positive for Env; however we were unable to
consistently detect env by PCR. This is not surprising since
the number of positively stained cells was relatively low and
would have been assigned a staining intensity of 2 in ac-
cordance with our grading scheme. It is possible, therefore,
that previous studies failed to identify JSRV DNA or RNA
in human adenocarcinoma in-situ and lung adenocarcin-
oma cases because the samples were of US origin [30].
Occupational exposure to meat and live animals is a risk
factor for developing lung cancer [45]. Persons who work
in abattoirs where sheep, cattle, and pigs are slaughtered
are exposed to livestock naturally infected with viruses that
cause cancer in the animals. Included among this group of
oncogenic viruses are JSRV and enzootic nasal tumor virus
(ENTV). A recent study evaluating mortality and cancer
incidence in two separate cohorts of workers from abat-
toirs (N = 4996) and meat processing plants (N = 3642),
confirmed that there is an excess occurrence of cancer, par-
ticularly of the lung, in both abattoir and processing plant
workers [33]. Similar results were previously reportedfor this and other related cohorts worldwide [34,46,47],
suggesting that steps should be taken to protect workers
from exposure to carcinogenic viruses in the workplace
and that there could potentially be health implications
for the general population which may also be exposed
to some of these viruses. Interestingly, a recent report
out of Europe suggests that professional exposure to
goats increases the risk of pneumonic-type lung adeno-
carcinoma in humans [48].
Conclusions
The association between JSRV and human lung cancer is
controversial; however, we have demonstrated the pres-
ence of an antigen that cross-reacts with a monoclonal
antibody specific for the JSRV Env protein in human lung
tumors and have amplified env- and gag-like sequences
from these samples raising the possibility that JSRV could
potentially contribute to lung tumorigenesis in humans.
With high-throughput next generation sequencing ap-
proaches, a JSRV-like virus in human lung cancers may be
identified which could have profound implications for pre-
vention, diagnosis and therapy.
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